News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis’ Investor Day on December 19: Agenda and Registration Details

December 14, 2023

Stockholm, Sweden, December 14, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the Agenda and Registration Details for the Company’s Investor Day on Tuesday December 19, 2023, in Stockholm, Sweden, for investors, analysts and media.
Time: Tuesday, December 19, 2023, at 3:00 pm – 6:00 pm CET (9:00 am – 12:00 pm ET)
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden
Registration (to attend in person): Please register by email to
Webcast (no preregistration required): Please follow this link
During the event, the Company will provide an update and review of its strategy and pipeline prospects. The presentations will focus on the Company’s drug candidate Emcitate (tiratricol) and the related unmet medical need it will address, development plans, commercial opportunities, and additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team, as well as invited key opinion leaders. Presentations will be held in English. The webcast will also be available on Egetis webpage after the event.

Time (CET) Subject Presenter(s)
15:00 Welcome, Corporate strategy and overview Nicklas Westerholm, CEO
15:15 Development of Emcitate for MCT8 deficiency patients Westerholm
15:30 MCT8 deficiency and the unmet medical need Dr Andrew Bauer, CHOP, Philadelphia, PA
15:50 Q&A Bauer & Westerholm
16:00 Global plans for commercializing Emcitate Henrik Krook, VP Commercial
16:15 Understanding MCT8 deficiency patients’ & caregivers’ needs Nigel Nicholls, Global Patient Advocacy Director
16:30 Improving disease awareness of MCT8 deficiency Peter Verwaijen, Global Head of Marketing & Brand Strategy
16:45 US launch preparations for Emcitate Anny Bedard, President Egetis North America
17:00 Q&A Krook, Nicholls, Verwaijen, Bedard, Westerholm
17:10 Break
17:30 RTH-beta and the unmet medical need Dr Carla Moran, University College Dublin
17:50 Q&A Moran & Westerholm
18:00 Concluding remarks Nicklas Westerholm, CEO




Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10